In the phase 3 EMERGENT-2 and EMERGENT-3 trials, Cobenfy met its primary end point, showing statistically significant ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

CPFT experts have launched a new service providing specialist advice and guidance with research to help people living with ...